Zura Bio to Present at Leerink Partners Global Healthcare Conference

HENDERSON, Nev. – On February 24, 2025, Zura Bio Limited (Nasdaq: ZURA), a clinical-stage, multi-asset immunology company, announced that senior members of its leadership team will participate in a fireside chat at the upcoming Leerink Partners Global Healthcare Conference. The session is scheduled for Tuesday, March 11, 2025, at 1:40 p.m. ET, during which executives will also host investor meetings in Miami, Florida.

The company’s presentation will be streamed live, with an archived replay available on its website’s Investors & Media section for at least 30 days following the event. This initiative is part of Zura Bio’s ongoing efforts to engage with investors and provide updates on its clinical development programs.

Zura Bio is advancing a portfolio of novel dual-pathway antibodies designed for the treatment of autoimmune and inflammatory diseases. The company is currently progressing three primary assets—tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880)—with Phase 1/1b clinical studies completed and further development planned to assess their efficacy, safety, and dosing convenience.

The announcement was made as part of a current report on Form 8-K filed with the Securities and Exchange Commission, which also included a press release detailing the company’s planned participation at the conference. The filing clarifies that the information is not deemed “filed” for the purposes of the liabilities under Section 18 of the Securities Exchange Act of 1934 unless specifically incorporated or stated.

Zura Bio’s participation at the conference reinforces its commitment to keeping the investment community informed about its progress in the competitive immunology space.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read JATT Acquisition’s 8K filing here.

JATT Acquisition Company Profile

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector.